Costimulatory Blockade and Use of mTOR Inhibitors: Avoiding Injury Part 2

David Wojciechowski, Flavio Vincenti

Research output: Contribution to journalReview article

Abstract

Kidney transplantation immunosuppression relies on a calcineurin inhibitor backbone. Calcineurin inhibitors have reduced early-acute rejection rates but failed to improve long-term allograft survival. Their nephrotoxicity has shifted the focus of investigation to calcineurin inhibitor–free regimens. Costimulation blockade with belatacept, a second generation, higher avidity variant of CTLA4-Ig, has emerged as part of a calcineurin inhibitor–free regimen. Belatacept has demonstrated superior glomerular filtration rate compared with calcineurin inhibitors albeit with an increased risk of early and histologically severe rejection. Focus on optimizing the belatacept regimen to reduce the acute rejection rate while maintaining superior renal function is underway. Belatacept has also been utilized as part of a calcineurin inhibitor–free conversion strategy in stable renal transplant recipients and has demonstrated superior improvement in glomerular filtration rate with conversion vs calcineurin inhibitor continuation. Additional work is underway to better define the role of belatacept in patients on calcineurin inhibitors with allograft dysfunction not due to rejection.

Original languageEnglish (US)
Pages (from-to)306-311
Number of pages6
JournalAdvances in Chronic Kidney Disease
Volume23
Issue number5
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Fingerprint

Calcineurin
Wounds and Injuries
Glomerular Filtration Rate
Allografts
Kidney
Kidney Transplantation
Immunosuppression
Abatacept
Calcineurin Inhibitors

Keywords

  • Belatacept
  • Costimulation blockade
  • mTOR inhibitors
  • Renal injury

ASJC Scopus subject areas

  • Nephrology

Cite this

Costimulatory Blockade and Use of mTOR Inhibitors : Avoiding Injury Part 2. / Wojciechowski, David; Vincenti, Flavio.

In: Advances in Chronic Kidney Disease, Vol. 23, No. 5, 01.09.2016, p. 306-311.

Research output: Contribution to journalReview article

@article{cb42332220024abea73210b5f99873c2,
title = "Costimulatory Blockade and Use of mTOR Inhibitors: Avoiding Injury Part 2",
abstract = "Kidney transplantation immunosuppression relies on a calcineurin inhibitor backbone. Calcineurin inhibitors have reduced early-acute rejection rates but failed to improve long-term allograft survival. Their nephrotoxicity has shifted the focus of investigation to calcineurin inhibitor–free regimens. Costimulation blockade with belatacept, a second generation, higher avidity variant of CTLA4-Ig, has emerged as part of a calcineurin inhibitor–free regimen. Belatacept has demonstrated superior glomerular filtration rate compared with calcineurin inhibitors albeit with an increased risk of early and histologically severe rejection. Focus on optimizing the belatacept regimen to reduce the acute rejection rate while maintaining superior renal function is underway. Belatacept has also been utilized as part of a calcineurin inhibitor–free conversion strategy in stable renal transplant recipients and has demonstrated superior improvement in glomerular filtration rate with conversion vs calcineurin inhibitor continuation. Additional work is underway to better define the role of belatacept in patients on calcineurin inhibitors with allograft dysfunction not due to rejection.",
keywords = "Belatacept, Costimulation blockade, mTOR inhibitors, Renal injury",
author = "David Wojciechowski and Flavio Vincenti",
year = "2016",
month = "9",
day = "1",
doi = "10.1053/j.ackd.2016.09.004",
language = "English (US)",
volume = "23",
pages = "306--311",
journal = "Advances in Chronic Kidney Disease",
issn = "1548-5595",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Costimulatory Blockade and Use of mTOR Inhibitors

T2 - Avoiding Injury Part 2

AU - Wojciechowski, David

AU - Vincenti, Flavio

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Kidney transplantation immunosuppression relies on a calcineurin inhibitor backbone. Calcineurin inhibitors have reduced early-acute rejection rates but failed to improve long-term allograft survival. Their nephrotoxicity has shifted the focus of investigation to calcineurin inhibitor–free regimens. Costimulation blockade with belatacept, a second generation, higher avidity variant of CTLA4-Ig, has emerged as part of a calcineurin inhibitor–free regimen. Belatacept has demonstrated superior glomerular filtration rate compared with calcineurin inhibitors albeit with an increased risk of early and histologically severe rejection. Focus on optimizing the belatacept regimen to reduce the acute rejection rate while maintaining superior renal function is underway. Belatacept has also been utilized as part of a calcineurin inhibitor–free conversion strategy in stable renal transplant recipients and has demonstrated superior improvement in glomerular filtration rate with conversion vs calcineurin inhibitor continuation. Additional work is underway to better define the role of belatacept in patients on calcineurin inhibitors with allograft dysfunction not due to rejection.

AB - Kidney transplantation immunosuppression relies on a calcineurin inhibitor backbone. Calcineurin inhibitors have reduced early-acute rejection rates but failed to improve long-term allograft survival. Their nephrotoxicity has shifted the focus of investigation to calcineurin inhibitor–free regimens. Costimulation blockade with belatacept, a second generation, higher avidity variant of CTLA4-Ig, has emerged as part of a calcineurin inhibitor–free regimen. Belatacept has demonstrated superior glomerular filtration rate compared with calcineurin inhibitors albeit with an increased risk of early and histologically severe rejection. Focus on optimizing the belatacept regimen to reduce the acute rejection rate while maintaining superior renal function is underway. Belatacept has also been utilized as part of a calcineurin inhibitor–free conversion strategy in stable renal transplant recipients and has demonstrated superior improvement in glomerular filtration rate with conversion vs calcineurin inhibitor continuation. Additional work is underway to better define the role of belatacept in patients on calcineurin inhibitors with allograft dysfunction not due to rejection.

KW - Belatacept

KW - Costimulation blockade

KW - mTOR inhibitors

KW - Renal injury

UR - http://www.scopus.com/inward/record.url?scp=84994181979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994181979&partnerID=8YFLogxK

U2 - 10.1053/j.ackd.2016.09.004

DO - 10.1053/j.ackd.2016.09.004

M3 - Review article

C2 - 27742385

AN - SCOPUS:84994181979

VL - 23

SP - 306

EP - 311

JO - Advances in Chronic Kidney Disease

JF - Advances in Chronic Kidney Disease

SN - 1548-5595

IS - 5

ER -